NRG Therapeutics
PrivateLast Round
Series B
Sep 8, 2025
Total Funding Raised
$95.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
NRG Therapeutics is a biotechnology company developing disease-modifying, brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) to treat neurodegenerative disorders such as Parkinson's disease and ALS.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NRG Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
NRG Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 8, 2025 | ||||
| Grant | Oct 31, 2024 | ||||
| Grant | Sep 5, 2024 | ||||
| Grant | Feb 22, 2023 | ||||
| Series A | Nov 9, 2022 | ||||
Grant | May 30, 2022 |
NRG Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Omega Funds | Series B, Series A |
| SV Health Investors | Series B |
| Parkinson's UK | Series A, Seed, Series B |
| M Ventures | Series B |
| British Business Bank | Series B |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 23, 2025
Kathryn Oliver appointed to newly created role.
- Oct 23, 2025
David Brocklebank appointed to newly created role.
NRG Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NRG Therapeutics's valuation, stock price, and market status.